| Title |
The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences
|
|---|---|
| Published in |
Targeted Oncology, August 2016
|
| DOI | 10.1007/s11523-016-0457-2 |
| Pubmed ID | |
| Authors |
Estelle Willems, Arnaud Lombard, Matthias Dedobbeleer, Nicolas Goffart, Bernard Rogister |
| Abstract |
The main obstacle for the cure of glioblastoma (GBM) is systematic tumor recurrence after treatment. More than 90 % of GBM tumors are indeed recurrent within 5 years after diagnosis and treatment. We urgently need new therapies to specifically address these deadly relapses. A major advance in the understanding of GBM recurrence is the identification of GBM-Initiating Cells (GIC), characterized by their abilities for self-renewal, multilineage differentiation, and proliferation. It appears that these features of GIC could be modulated by the mitotic kinase Aurora A (AurA). Indeed, besides its role in mitosis, AurA has recently been identified to regulate alternative functions like cell polarity, asymmetric cell division, and epithelial to mesenchymal transition. All these properties may help explain GBM therapeutic resistance and recurrence. In this review, we make the hypothesis that AurA could significantly contribute to GBM recurrences and we focus on the possible roles of AurA in GIC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 31% |
| Student > Bachelor | 5 | 16% |
| Researcher | 5 | 16% |
| Student > Doctoral Student | 3 | 9% |
| Student > Postgraduate | 3 | 9% |
| Other | 5 | 16% |
| Unknown | 1 | 3% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 10 | 31% |
| Agricultural and Biological Sciences | 6 | 19% |
| Medicine and Dentistry | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 5 | 16% |
| Chemistry | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 1 | 3% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2017.
All research outputs
#20,420,242
of 22,971,207 outputs
Outputs from Targeted Oncology
#514
of 555 outputs
Outputs of similar age
#295,278
of 338,235 outputs
Outputs of similar age from Targeted Oncology
#5
of 6 outputs
Altmetric has tracked 22,971,207 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 555 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,235 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.